| Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome (NCT05361668) | Crinetics Pharmaceuticals Inc. | 2022-04-22 |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (NCT05477576) | RayzeBio, Inc. | 2022-03-24 |
| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors (NCT05263050) | Fox Chase Cancer Center | 2022-01-21 |
| Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes (NCT04907643) | Cedars-Sinai Medical Center | 2021-10-05 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy (NCT04039516) | King's College Hospital NHS Trust | 2020-10-01 |
| Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging (NCT04017104) | British Columbia Cancer Agency | 2019-11-01 |
| Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors (NCT03420521) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-03-09 |
| Personalized PRRT of Neuroendocrine Tumors (NCT02754297) | CHU de Quebec-Universite Laval | 2016-04-12 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) (NCT02628067) | Merck Sharp & Dohme LLC | 2015-12-18 |
| Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors (NCT02399215) | Roswell Park Cancer Institute | 2015-05-15 |
| Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors (NCT01782443) | Dana-Farber Cancer Institute | 2013-02-13 |
| Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (NCT01466036) | Dana-Farber Cancer Institute | 2012-07-01 |
| A Study of Axitinib in Advanced Carcinoid Tumors (NCT01435122) | H. Lee Moffitt Cancer Center and Research Institute | 2011-10-25 |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. (NCT01398306) | University Medical Center Groningen | 2011-07-01 |
| Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor (NCT01175096) | Guangdong Provincial People's Hospital | 2010-07-01 |
| AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors (NCT01024387) | Dana-Farber Cancer Institute | 2010-03-01 |
| Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (NCT00942682) | Dana-Farber Cancer Institute | 2009-07-01 |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (NCT00804336) | Dana-Farber Cancer Institute | 2008-10-01 |
| Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma (NCT00780663) | Cylene Pharmaceuticals | 2008-10-01 |
| SwissNET - a Registry for Neuroendocrine Tumours in Switzerland (NCT01039922) | Insel Gruppe AG, University Hospital Bern | 2008-01-01 |
| Clinical and Pathologic Studies in Neuroendocrine Tumors (NCT00657332) | Stanford University | 2007-07-01 |
| Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor (NCT00412061) | Novartis Pharmaceuticals | 2006-12-01 |
| Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease (NCT00446082) | Novartis Pharmaceuticals | 2006-06-01 |
| A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors (NCT00328497) | CASI pharmaceuticals, Inc. | 2006-05-01 |
| The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022 (NCT07291752) | Suez Canal University | 2000-12-01 |
| A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022 (NCT07317713) | Suez Canal University | 2000-12-01 |
| Endoscopic Treatment of Bronchial Carcinoid Tumors (NCT03723499) | Centre Hospitalier Universitaire de Saint Etienne | 1995-11-01 |